A study led by U.S.-based biotechnology company AOA Dx has revealed that a novel blood test can effectively identify ovarian cancer at an early stage with an accuracy rate of 92%. This achievement is considered a major breakthrough in women’s cancer screening and could potentially address the long-standing challenge of early diagnosis.
Ovarian cancer is often referred to as the “silent killer” of gynecologic tumors. Because early symptoms are mild and nonspecific, more than 70% of patients are diagnosed at stage III or IV. This late detection is a major factor behind the persistently low 5-year survival rate of only 30%–40%. Currently, clinical practice relies mainly on imaging and the serum biomarker CA125. However, both approaches lack sufficient sensitivity, making them inadequate for early screening.
The newly developed test integrates multiple novel biomarkers and applies machine learning algorithms for data analysis. In validation studies across several clinical centers, the test achieved an 88% detection rate for stage I–II ovarian cancer and an overall accuracy of 92% — significantly outperforming existing screening methods.
The research team emphasized that the method is simple to administer and cost-effective, with the potential to be incorporated into routine health examinations, allowing more women to benefit from early diagnosis and timely intervention.
Independent experts from Cancer Research UK (CRUK) described the findings as “exciting,” with the potential to significantly improve ovarian cancer cure rates. However, they cautioned that the results are based on preliminary clinical studies, and large-scale trials are still required to confirm generalizability and long-term clinical value.
Next Steps
AOA Dx announced plans to advance the test into Phase III clinical trials within the next two years and is actively seeking collaborations with global medical institutions to implement it in high-risk populations. If regulatory approval is granted, this blood test could become a critical tool for the early detection of ovarian cancer.
